Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Documentation of the Safety and Effectiveness Profile of the IgG Immunoadsorber GLOBAFFIN® in Clinical Routine (SEPIAR)

NCT04078698 is registered in ClinicalTrials.gov with Fresenius Medical Care Deutschland GmbH as lead sponsor.

NCT NCT04078698
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04078698 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Documentation of the Safety and Effectiveness Profile of the IgG Immunoadsorber GLOBAFFIN® in Clinical Routine (SEPIAR)
Lead sponsor
Fresenius Medical Care Deutschland GmbH
Phase
Not applicable
Overall status
Completed
Start date
September 5, 2019
Completion date
August 15, 2025
Enrollment
34 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

autoimmune diseases